AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany

March 21, 2019 Off By BusinessWire

ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX
Therapeutics, Inc. (NYSE American: AGE), a biotechnology company
focused on innovative therapeutics for human aging, announced today that
the company will present in multiple sessions at Undoing
Aging 2019, March 28-30 in Berlin, Germany.

Details of the company’s participation follow:

Thursday, March 28, 7:00pm CET: “Debate: is comprehensive damage
repair feasible?” with Aubrey de Grey, Ph.D., AgeX’s VP, New
Technology Discovery and Vadim Gladyshev, Ph.D., Professor of Medicine
at Harvard Medical School.

Friday, March 29, 10:00am CET: As part of the track “Restoring
Cellular Youth,” AgeX’s Founder and CEO Michael D. West, Ph.D.,
will deliver an update on the Company’s regenerative medicine product
development, and in addition, present for the first time data relating
to central molecular aging clockwork mechanisms the Company is
targeting with its induced Tissue Regeneration (iTR^TM)
program.

The conference also features a track, “Senolysis,” inspired in part by
Dr. West’s research:

“It has been two decades since West and Campisi began to suggest that
senescent cells might be more than just disabled, but actively toxic.
Since 2011, their idea has not only been confirmed in the lab but has
spawned a huge range of ideas for eliminating such cells, many of which
are already being pursued in startups. The rate of progress is such that
a single session at UA can no longer do justice to it – so, we’re having
two!”

A copy of Dr. West’s presentation will be made available on the AgeX
website.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing
and commercializing innovative therapeutics for human aging. Its PureStem^® and
UniverCyte^™manufacturing and immunotolerance technologies
are designed to work together to generate highly defined, universal,
allogeneic, off-the-shelf pluripotent stem cell-derived young cells of
any type for application in a whole host of diseases with a high unmet
medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat
cells) for Type II diabetes. AgeX’s revolutionary longevity platform
named induced Tissue Regeneration (iTR™) aims to unlock cellular
immortality and regenerative capacity to reverse age-related changes
within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical
development. HyStem^® is AgeX’s delivery technology to stably
engraft PureStem cell therapies and slowly release iTR molecules in the
body. AgeX is developing its core product pipeline for use in the clinic
to extend human healthspan, and is seeking opportunities to form
licensing and partnership agreements around its broad IP estate and
proprietary technology platforms for non-core clinical applications.

For more information, please visit www.agexinc.com
or connect with the company on Twitter,
Facebook
and YouTube.

Forward-Looking Statements

Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not historical fact
including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
should also be considered forward-looking statements. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the business of AgeX Therapeutics, Inc. and
its subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of AgeX’s
Information Statement filed as an exhibit to its Registration Statement
on Form 10 with the Securities and Exchange Commissions (copies of which
may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. AgeX specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.